Trial Profile
Phase I Open-Label Study of Fostamatinib, a SYK Inhibitor, in Patients With Lower-Risk Myelodysplastic Syndromes or Chronic Myelomonocytic Leukemia Who Have Failed Therapy With Hypomethylating Agents
Status:
Recruiting
Phase of Trial:
Phase I
Latest Information Update: 07 Apr 2023
Price :
$35
*
At a glance
- Drugs Fostamatinib (Primary)
- Indications Chronic myeloid leukaemia; Myelodysplastic syndromes
- Focus Adverse reactions
- 04 Apr 2023 Planned End Date changed from 26 Mar 2023 to 30 Apr 2025.
- 04 Apr 2023 Planned primary completion date changed from 26 Mar 2023 to 30 Apr 2025.
- 13 Dec 2022 Preliminary results (n=5) presented at the 64th American Society of Hematology Annual Meeting and Exposition.